Literature DB >> 10883667

Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas.

Y Z Shi1, A M Hui, T Takayama, X Li, X Cui, M Makuuchi.   

Abstract

To investigate the relationship between the expression of p21(WAF1/CIP1) protein and p53 status and the possible role of the two proteins in hepatocellular carcinomas (HCCs), we examined the expression of p21(WAF1/CIP1) and p53 immunohistochemically in 81 tumours from 65 patients with hepatocellular carcinoma. p21(WAF1/CIP1) protein was absent from 59 of 81 tumours (72.8%), and altered p53 expression was found in 43 (53.1%). p21(WAF1/CIP1) expression was significantly associated with p53 status (P = 0.0008); 38 of 59 tumours lacking p21(WAF1/CIP1) protein were accompanied by altered p53 expression. Further analyses showed that p21(WAF1/CIP1) expression was inversely correlated with p53 expression in hepatitis C virus (HCV)-related HCCs, but not in HBV-related hepatocellular carcinomas and hepatocellular carcinomas without viral infection. All 11 tumours with intrahepatic metastasis showed altered p21(WAF1/CIP1) or p53 expression. In contrast, no intrahepatic metastasis was found in any of the 17 tumours without abnormal expression of either of the two proteins. These results suggest that: (1) different modes of p21(WAF1/CIP1) regulation are involved in HCCs differing in their hepatitis viral infection status, and p21(WAF1/CIP1) expression appears to be predominantly related to altered p53 in HCV-related HCCs; (2) disruption of the p53-p21(WAF1/CIP1) cell-cycle-regulating pathway may contribute to malignant progression of HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883667      PMCID: PMC2374549          DOI: 10.1054/bjoc.2000.1310

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

Review 1.  Molecular basis of multistep hepatocarcinogenesis: genetic and epigenetic events.

Authors:  A M Hui; M Makuuchi
Journal:  Scand J Gastroenterol       Date:  1999-08       Impact factor: 2.423

2.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology.

Authors:  P A Hall; A Ray; N R Lemoine; C A Midgley; T Krausz; D P Lane
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

3.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma.

Authors:  A M Hui; X Li; M Makuuchi; T Takayama; K Kubota
Journal:  Int J Cancer       Date:  1999-12-22       Impact factor: 7.396

6.  Wild-type p53 activates transcription in vitro.

Authors:  G Farmer; J Bargonetti; H Zhu; P Friedman; R Prywes; C Prives
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

8.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

9.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  13 in total

1.  Hepatomegaly in transgenic mice expressing the homeobox gene Cux-1.

Authors:  Gregory B Vanden Heuvel; Jennifer G Brantley; Neal I Alcalay; Madhulika Sharma; Gabor Kemeny; Joshua Warolin; Aric W Ledford; David M Pinson
Journal:  Mol Carcinog       Date:  2005-05       Impact factor: 4.784

2.  Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721.

Authors:  Jian-Hui Qu; Ming-Hua Zhu; Jing Lin; Can-Rong Ni; Fang-Mei Li; Zhi Zhu; Guan-Zhen Yu
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

3.  Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines.

Authors:  Zhi-ming Wu; Chun Dai; Ying Huang; Cui-fang Zheng; Qiong-zhu Dong; Guan Wang; Xiao-wen Li; Xiao-fei Zhang; Bin Li; Gang Chen
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

4.  Differential expression of cell cycle regulators in HCV-infection and related hepatocellular carcinoma.

Authors:  Azza E El Bassiouny; Mona M Nosseir; Mona K Zoheiry; Noha A Ameen; Ahmed M Abdel-Hadi; Ibrahim M Ibrahim; Suher Zada; Abdel-Hakeem Saad El-Deen; Nora E El-Bassiouni
Journal:  World J Hepatol       Date:  2010-01-27

5.  Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo.

Authors:  Elizabeth A Slee; Barbara Benassi; Robert Goldin; Shan Zhong; Indrika Ratnayaka; Giovanni Blandino; Xin Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-20       Impact factor: 11.205

Review 6.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

7.  Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.

Authors:  Cheng-Tang Chiu; Ta-Sen Yeh; Jui-Chen Hsu; Mün-Fu Chen
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

8.  Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis.

Authors:  Holger Willenbring; Amar Deep Sharma; Arndt Vogel; Andrew Y Lee; Andreas Rothfuss; Zhongya Wang; Milton Finegold; Markus Grompe
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

9.  Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.

Authors:  T K Said; R C Moraes; R Sinha; D Medina
Journal:  Breast Cancer Res       Date:  2000-12-22       Impact factor: 6.466

10.  A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells.

Authors:  Y Gong; S Deng; M Zhang; G Wang; G Y Minuk; F Burczynski
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.